Caricamento...
PARP inhibition — not all gene mutations are created equal
Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improve...
Salvato in:
| Pubblicato in: | Nat Rev Urol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7959484/ https://ncbi.nlm.nih.gov/pubmed/30498248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41585-018-0129-3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|